Evaluation of Hemostatic Factors in Patients Undergoing Major Hepatic Resection and Other Major Abdominal Surgeries

2011 ◽  
Vol 77 (9) ◽  
pp. 1188-1193 ◽  
Author(s):  
Elliot B. Tapper ◽  
Ken A. Tanaka ◽  
Juan M. Sarmiento
Keyword(s):  
Hepatic Resection ◽  
Prothrombin Time ◽  
Perioperative Management ◽  
Antithrombin Iii ◽  
Major Hepatectomy ◽  
International Normalized Ratio ◽  
Major Hepatic Resection ◽  
Additional Testing ◽  
Hemostatic Factors ◽  
Single Blind

The aim of this study was to evaluate the role for additional testing of coagulation in perioperative management of patients undergoing major hepatic resection. Major outcome measures were perioperative measurements of hemostatic factors (activated partial prothrombin time [aPTT], prothrombin time/international normalized ratio, fibrinogen, antithrombin-III). We conducted a prospective, single-blind study comparing hemostatic factors in patients undergoing major hepatectomy, Whipple procedures, and other gastrointestinal operations. Ninety-five consecutive patients were enrolled. No values differed significantly at baseline. Immediately postoperative, only international normalized ratio was significantly lower comparing major hepatectomy with Whipple ( P < 0.005) and other procedures ( P < 0.0032). Twenty-four hours postoperative, antithrombin-III was lower for major hepatectomy than Whipple ( P < 0.028) and others ( P < 0.0001); fibrinogen was lower compared with Whipple ( P < 0.014) and others ( P < 0.0009); international normalized ratio was lower to compared with Whipple ( P < 0.0001) and others ( P < 0.0001). aPTT measurements never differed significantly between groups at any time. Antithrombin-III and fibrinogen only correlated with international normalized ratio and aPTT for the other procedures. Additional hemostatic values beyond the standard evaluations of aPTT and international normalized ratio are needed to better assess patients undergoing major hepatic surgery.

Calibration of a Lyophilized Pooled Plasma as Candidate Reference Plasma for Standardization of the Prothrombin Time Ratio

1993 ◽  
Vol 13 (02) ◽  
pp. 96-105 ◽  
Author(s):  
H. Beeser ◽  
U. Becker ◽  
H. J. Kolde ◽  
E. Spanuth ◽  
P. Witt ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
International Study ◽  
International Normalized Ratio ◽  
Measurement Methods ◽  
Factor V ◽  
Diagnostic Instruments ◽  
Plasma Pool ◽  
Normal Plasma ◽  
German Association ◽  
Prothrombin Time Ratio

SummaryThe prothrombin time (PT), obtained from a fresh normal plasma pool (FPP), is the basis both for the establishment of the 100% activity (normal plasma) and for the ratio calculation used in the International Normalized Ratio (INR) according to the recommendations of the ICSH/ICTH (6). Today the PT of lyophilized normal plasma pools are successfully used as reference for the assessment of samples in proficiency studies. However, a lack of comparability is to be recognized. Therefore the Committee of Hematology of the German Association of Diagnostics’ and Diagnostic Instruments’ Manufacturers (VDGH) decided to produce a candidate reference plasma (VDGH Reference Plasma) which was calibrated against fresh normal plasma pools in an international study.The basic calibration was performed by using the same certified BCR thromboplastin (BCT/099) by all participants. The endpoint was determined manually and by using the coagulometer Schnitger-Gross. In additional testings each participant used his own routine thromboplastins and methods. Calculating the ratio [PT VDGH Reference Plasma (sec)/PT fresh normal plasma pool (sec)] the VDGH Reference Plasma showed a deviation from the average fresh normal plasma pool of 1.05 both with the BCT/099 and with all thromboplastins. There were obtained some statistical differences between “plain” and “combined’’ (added factor V and fibrinogen) thromboplastins. No statistical difference was found between the different endpoint measurement methods (manual, mechanical, optical).In spite of these statistical deviations the VDGH Reference Plasma can be used for the standardization of the PT-normal (100%) value with different ratios for plain (1.06) and combined (1.02) thromboplastins. The manufacturers will use this VDGH Reference Plasma for the calibration of their commercially available calibration plasmas, which allows the user of such a material to calculate a calibrated 100% PT value.

scholarly journals The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Sofia Dahlberg ◽  
Ulf Schött ◽  
Thomas Kander
Keyword(s):  
Propensity Score ◽  
Prothrombin Time ◽  
Critically Ill ◽  
Vitamin K ◽  
Critically Ill Patients ◽  
International Normalized Ratio ◽  
University Hospital ◽  
Red Blood Cell Transfusion ◽  
Registry Study ◽  
Exclusion Criteria

Abstract Background Previous studies have indicated that vitamin K deficiency is common in non-bleeding critically ill patients with slightly prolonged prothrombin time-international normalized ratio (PT-INR). It has never been investigated thoroughly whether the administration of vitamin K to these patients could affect their PT-INR. Therefore, the aim of this registry study was to evaluate changes in PT-INR in response to vitamin K in critically ill patients with PT-INR in the range of 1.3–1.9. Methods Patients admitted to a mixed 9-bed general intensive care unit at a University Hospital, between 2013 and 2019 (n = 4541) with a PT-INR between 1.3 and 1.9 at any time during the stay were identified. Patients who received vitamin K with appropriate sampling times for PT-INR and without exclusion criteria were matched with propensity score to patients from the same cohort who did not receive vitamin K (controls). PT-INR was measured at admission, within 12 h before vitamin K administration and 12–36 h following vitamin K administration. Exclusion criteria included pre-existing liver cirrhosis, any plasma or platelet transfusion, or > 1 unit red blood cell transfusion between PT-INR samplings. Results Propensity score matching resulted in two groups of patients with 129 patients in each group. PT-INR decreased in both groups (1.4 [1.3–1.4] in the vitamin K group and 1.4 [1.3–1.6] in the controls, p < 0.001 and p = 0.004, respectively). The decrease in PT-INR was slightly more pronounced in patients who received vitamin K (delta PT-INR − 0.10 [− 0.30 to − 0.10] in the vitamin K group and − 0.10 [− 0.20 to 0.10] in the controls, p = 0.01). Conclusion In critically ill patients with a PT-INR of 1.3–1.9, the administration of vitamin K resulted in a slightly larger decrease of PT-INR 12–36 h after administration compared to controls. Future studies should focus on identifying which patient populations may benefit most from vitamin K administration as well as whether vitamin K could be a better alternative than plasma or prothrombin complex concentrate to improve PT-INR before non-emergent invasive procedures.

A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology

Hepatology ◽  
2007 ◽  
Vol 46 (2) ◽  
pp. 528-534 ◽  
Author(s):  
Laurent Bellest ◽  
Valérie Eschwège ◽  
Raoul Poupon ◽  
Olivier Chazouillères ◽  
Annie Robert
Keyword(s):  
Prothrombin Time ◽  
International Normalized Ratio

Reduction in the morbidity and mortality of major hepatic resection

1982 ◽  
Vol 144 (6) ◽  
pp. 740-743 ◽  
Author(s):  
William H. Ryan ◽  
Brian W. Hummel ◽  
Robert N. McClelland
Keyword(s):  
Hepatic Resection ◽  
Morbidity And Mortality ◽  
Major Hepatic Resection

Outpatient Use of a Portable International Normalized Ratio/Prothrombin Time Monitor

1994 ◽  
Vol 87 (2) ◽  
pp. 206-210 ◽  
Author(s):  
RICHARD H. WHITE ◽  
DANIEL M. BECKER ◽  
MICHAEL G. GUNTHER-MAHER
Keyword(s):  
Prothrombin Time ◽  
International Normalized Ratio

Major Hepatic Resection: An Update

1990 ◽  
Vol 83 (1) ◽  
pp. 18-22 ◽  
Author(s):  
WILLIAM H. EDWARDS ◽  
JOHN L. SAWYERS ◽  
R BENTON ADKINS
Keyword(s):  
Hepatic Resection ◽  
Major Hepatic Resection

scholarly journals Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban

2018 ◽  
Vol 24 (9_suppl) ◽  
pp. 188S-193S
Author(s):  
Jen-Hung Huang ◽  
Yung-Kuo Lin ◽  
Cheng-Chih Chung ◽  
Ming-Hsiung Hsieh ◽  
Wan-Chun Chiu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Prothrombin Time ◽  
Factor Xa ◽  
International Normalized Ratio ◽  
Biochemical Properties ◽  
Study Patient ◽  
Group 3 ◽  
Multiple Variables ◽  
Group 2 ◽  
Group 1

Rivaroxaban, a direct factor Xa inhibitor, is widely used to reduce the chance of stroke in patients with atrial fibrillation (AF). It is not clear why the prothrombin time (PT) of the international normalized ratio (INR) fails to correlate with treatment using rivaroxaban in patients with AF. In this study, patient characteristics, the rivaroxaban dosage, AF type, drug history, biochemical properties, and hematological profiles were assessed in patients treated with rivaroxaban. In 69 patients with AF receiving rivaroxaban, 27 (39.1%) patients had a normal INR (≤1.1, group 1), 27 (39.1%) patients had a slightly prolonged INR (1.1∼1.5, group 2), and 15 (21.7%) patients had a significantly prolonged INR (>1.5, group 3). Group 1 patients had a higher incidence of a stroke history than did patients in group 2 ( P = .026) and group 3 ( P = .032). We scored patients with a persistent AF pattern (1 point), paroxysmal AF pattern (0 point), renal function (ie, the creatinine clearance rate in mL/min/1.73 m2 of >60 as 0 points, of 30∼60 as 1 point, and of <30 as 2 points), and no history of stroke (1 point), and we found that group 3 had a higher score than groups 2 or 1 (2.9 ± 0.8, 2.4 ± 0.7, and 2 ± 0.7, respectively; P < .05). There were similar incidences of bleeding, stroke, and unexpected hospitalizations among the 3 groups. The PT of the INR is determined by multiple variables in patients with AF receiving rivaroxaban. Rivaroxaban-treated patients with AF having different INR values may have similar clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document